Dr. John Cush RheumNow
4 years 9 months ago
FDA Puts Boxed Warnings on JAK Inhibitors
Based on the safety review of tofacitinib in Pfizer's Oral Surveillance study, the FDA has formalized the recommendation that patients should be started on a TNF inhibitor (TNFi) before trying a JAK inhibitor.
https://t.co/bXZ4Yedyyv https://t.co/tsvHOtIEK0
Dr. John Cush RheumNow
4 years 9 months ago
ICYMI: Risks associated with mortality in VEXAS
https://t.co/mpAc5shaMq https://t.co/FdOQcfwusp
Dr. John Cush RheumNow
4 years 9 months ago
ICYMI: Zoom Fatigue is real. Study shows fatigue is from being on-cam that triggers self-presentation - the needs to monitor how you look to others; more common in women. Suggest: reduce monitor/image size & Turn off Self view (avoid self evaluation) https://t.co/vS8tJv9Kpd https://t.co/F7mHdYgOXy
Dr. John Cush RheumNow
4 years 9 months ago
New podcast up!
Drs. Jack Cush and Martin Bergman review the topic of treat-to-target (T2T) management in rheumatology.
Both will debate the pro's and con's of the T2T strategy at the upcoming RWCS meeting on Feb. 17, 2022.
https://t.co/oe6hsAq2KG https://t.co/1sbTmd9cnV
Dr. John Cush RheumNow
4 years 9 months ago
Download Available! The Scary Side of Steroid.
Log in and download today.
https://t.co/sYVWGTVHgx https://t.co/NIbi49SJEo
Dr. John Cush RheumNow
4 years 9 months ago
AURORA 2 results were presented at #ACR21 - a continuation study of voclosporin in 116 active Lupus Nephritis pts randomized to either PBO or voclosporin. After 36 mos the VOC group had stable GFR and reduction in proteinuria https://t.co/O7G1dCIzbP
Drs. Jack Cush and Martin Bergman review the topic of treat-to-target (T2T) management in rheumatology.
Both will debate the pro's and con's of the T2T strategy at the upcoming RWCS meeting on Feb. 17, 2022.
You can register and learn more about the meeting at: https://r-w-c-s.com/2022/
Dr. John Cush RheumNow
4 years 9 months ago
ASK CUSH ANYTHING!
Have a Rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.
https://t.co/tl3Nkxdv0B https://t.co/WwxgWGuVcC
Dr. John Cush RheumNow
4 years 9 months ago
Check out our blog by Dr. Kathryn Dao ( @KDAO2011) on "Redefining Aging."
https://t.co/GbE77GTa0y https://t.co/e2GYETqsUR
Dr. John Cush RheumNow
4 years 9 months ago
CBD and Opioids in PsA : Dr. Eric Ruderman ( @JointMD) reviews abstract #1456 and #1777 presented at the ACR21 annual meeting.
https://t.co/ZATSfzqj51 https://t.co/dhFwgS9b6J
Dr. John Cush RheumNow
4 years 9 months ago
Should we start considering therapeutic drug monitoring when prescribing TNFi for treatment of our rheumatologic conditions?
https://t.co/RbOlrnW54O https://t.co/iDlqwv32zs
Patients with clinically suspect arthralgia can represent a challenge for clinicians, in a sense that there are not yet reliable markers to predict evolution to clinical RA nor enough evidence to support routine prescription of conventional synthetic DMARDS or biologic treatments in this setting.
Excess adiposity and genetic predisposition both contributed to risk of gout among U.S. women, with the risks being highest when both factors are present, a large prospective study found.
